HMGCR and myopathy: However, despite having significantly greater oral bioavailability compared to lovastatin (18% vs. 5%), pravastatin has approximately 50% lower binding affinity for HMG-CoA reductase, consequently mitigating the potency of the drug and the possibility of myopathy [39,41].